QUOTE AND NEWS
Business Wire  May 3  Comment 
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced today the release of Version 3.0 of its MedChem Studio™ and Version 2.0 of
Business Wire  Apr 27  Comment 
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced today the release of Version 8.0 of its flagship GastroPlus™ simulation
Business Wire  Apr 19  Comment 
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today the release of ADMET Predictor™ Version 6.0 with an impressive set of expanded and powerful
Business Wire  Apr 17  Comment 
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per
Business Wire  Apr 11  Comment 
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that further testing shows that the newest molecule the Company has designed to inhibit the
Business Wire  Apr 10  Comment 
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2012 ended February 29, 2012 (2QFY12).
Business Wire  Apr 9  Comment 
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2012
Business Wire  Mar 15  Comment 
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that preliminary testing shows that one of the molecules it has designed to inhibit the malaria
Business Wire  Mar 7  Comment 
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has agreed to buy out the software royalty agreement with Enslein Research of Rochester,
Business Wire  Mar 6  Comment 
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced the promotion of Mr. John DiBella to the position of Vice President of Marketing and Sales.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki